Issue link: http://osercommunicationsgroup.uberflip.com/i/499812
C h a i n D r u g s t o r e D a i l y 2 5 S u n d a y, A p r i l 2 6 , 2 0 1 5 more than 80 million prescriptions are filled in a year with Mallinckrodt generics products. We hold a strong position in the U.S. controlled sub- stances generics market – where we have expertise – and we have an ADHD franchise. Mallinckrodt also has a well-respected addiction treat- ment product line, providing value- added educational support to clinics. CDD: What differentiates Mallinckrodt as a specialty generics provider? WK: Some people view specialty gener- ics just as a commodities business where price is the only driver. However, we see that our customers want more than just a supplier; they want a strategic partner. That is why Mallinckrodt has focused on staying customer-centric, demonstrating what we can bring to a client relationship aside from competitive pricing and by providing a customized and connected customer service experience. CDD: Where does Mallinckrodt stand on abuse-deterrence technology? WK: We support abuse-deterrence. We believe the best position is to ensure there is a balanced approach to the conversion of all drugs – branded and generic – to abuse-deterrent formulations to ensure no gaps in patient access to the medicines they rely on to help. We have research efforts focusing on exploring the abuse- deterrent potential of our proprietary for- mulation technologies. Our goal is to develop abuse-deterrent technologies that can be used in both branded and generic medicines that will effectively make our products less attractive to potential abusers, while at the same time providing Mallinckrodt Pharmaceuticals (Cont'd. from p. 1) patients who depend on our medicines for relief of diagnosed pain with a wide range of safe, affordable options. CDD: How did the company respond to the U.S. DEA's hydrocodone rescheduling? WK: We had been preparing for this change and assumed it would occur. When the DEA rescheduled hydrocodone com- bination products, in just six weeks Mallinckrodt had a complete new line of products and was able to manage the sig- nificantly more sophisticated material handling and storage requirements needed to comply with Schedule II standards. We will continue to work with DEA, patient and provider groups, and other stakehold- ers to lessen the impact of this change on legitimate pain patients who struggle to have their pain medication needs met. CDD: What is Mallinckrodt doing in the area of responsible use of pain medications? WK: Mallinckrodt is committed to sup- porting solutions that reduce the ongoing issues of opioid abuse, misuse and addic- tion. We support a broad range of pro- grams that encourage and support appro- priate use of pain medications. One recent example is the company's donation of more than 120,000 medication inactiva- tion pouches to healthcare providers to provide patients a safe, convenient and environmentally friendly way to dispose of unused medications. The donation of medication inactivation pouches to 5,000 U.S. physicians is designed to help fur- ther build awareness of patient safety and responsible drug disposal as well as rein- force Mallinckrodt's commitment to responsible use of pain medications. For more information, visit booth #318 or call 314.654.2000. understanding in the health care legal space. We understand the laws and regu- lations that healthcare enterprises face in all aspects of their businesses and uphold a standard of providing high-quality, exceptional and pragmatic legal advice. In addition, Much Shelist has nearly 100 attorneys who practice in many other areas of the law, including labor and employment, intellectual property, com- plex litigation and corporate transactions, just to name a few. CDD: What kind of legal challenges do health care enterprises face? NM: Today's health care enterprises face a number of legal challenges, including regulatory compliance issues, private party litigation, payor contract issues, transactional matters (such as mergers and acquisitions), and defending against both federal and state government inves- tigations. With our understanding of legal issues in general, and drug and pharmacy law specifically, we are ready to provide trusted advice in all of these areas. CDD: Who in the health care industry will benefit most from Much Shelist's services? NM: Our firm has strong general health care experience as well as an in-depth understanding of drug and pharmacy law, and we represent all entities along the supply chain. We represent manufactur- ers, wholesale distributors, third-party logistics providers, pharmacies and tech- nology companies. As trusted legal advi- Much Shelist (Cont'd. from p. 1) sors, we provide top legal counseling and advice that our clients can depend on time and again. CDD: Can you tell us how your history in health care helps you bring optimal service to your clients? NM: Well, I am a pharmacist and an attorney and I understand health care, specifically drug and pharmacy law. I practiced pharmacy for almost 10 years, having worked as a licensed pharmacist in hospitals as well as in the retail setting. I received my pharmacy degree from The Ohio State University, a Doctor of Pharmacy from the University of Illinois and a law degree from The John Marshall Law School. Currently, I am in my sec- ond term as vice-chair of the Illinois State Board of Pharmacy. I also write a monthly legal and regulatory column in the national magazine "Drug Topics." I know how healthcare works in practice and the legal challenges that arise with managing and bringing healthcare servic- es to market. CDD: Is there anything else you'd like to tell our readers? NM: Much Shelist is a full-service law firm with a nationally known drug and pharmacy law practice. We understand the legal challenges that clients face and we advocate on behalf of our clients every day. For more information, contact Ned Milenkovich, PharmD, JD at nmilenkovich@muchshelist.com or call 312.521.2482. many as 30 percent fall off within 30 days while up to 60 percent fall off within 180 days. Remember, these are patients who have a diagnosed condi- tion and need the treatment that they've been prescribed. Patient outcomes are increasingly the basis for how the healthcare industry is measured and compensated. Like other healthcare providers, the retail pharmacy business is under enormous pressure to provide cost-effective quality care, and nonad- herence is a major barrier. Nearly $300 billion is lost every year in avoidable medical spending due to medication nonadherence. CDD: What can be done about that? RS: The Adheris Health approach edu- cates patients on the benefits of living a healthier life so they see the value in starting and staying on therapy. Our approach makes the pharmacist a critical partner to brand marketers. We recognize that the pharmacy is the backbone of adherence by providing critical interven- tions at the point of care and addressing gaps in care, and we partner with the best organizations in the business to advance patient health. CDD: Adheris Health has offered adher- ence-focused programs for many years. What's changed? Adheris (Cont'd. from p. 1) RS: As part of inVentiv Health, we have access to more resources than ever – including scientific expertise that makes our consulting services much stronger. Our Behavioral Insights group is the perfect example. It's a wide array of experts – health psychologists, behavioral scientists, clinical special- ists, consumer marketers, design experts and user experience specialists – who, together, interpret our vast data resources to develop and implement a personalized, multichannel approach to reaching patients wherever they are in their treatment journey. CDD: Why put so much expertise to work on adherence? RS: At a very basic level, we have the opportunity – even an obligation – to help patients live healthier lives, and good habits like adherence are critical behaviors that we can encourage. In the past, there have been so many uncoordi- nated, unfocused attempts to boost adher- ence and, as you'd expect, the results were inconsistent. That's why we've cre- ated the first and only consultancy equipped to take a big-picture, strategic view of adherence – with vast resources to help marketers motivate better out- comes in the patient base they've worked so hard to acquire. For more information visit booth #454 or visit www.adherishealth.com. supermint, pink grapefruit mint and moji- to mint, with more ADA-approved pastes to come. Hello's signature flavors are clinically proven to prevent cavities and strengthen enamel. They safely polish teeth with a gentle silica and freshen breath, while being free from preserva- tives, dyes, triclosan, microbeads and artificial sweeteners, and they feature xylitol and stevia. According to Dubitsky, hello's newest adult flavor toothpaste, peach mango mint, is "so delicious that users will develop crushes on their brushes." In addition, hello new range of kids natural- ly friendly toothpaste is free from mint and comes in kid-friendly flavors includ- ing bubble gum, green apple and blue raspberry. Like the adult paste, hello kids toothpaste prevents cavities, polishes teeth and strengthens enamel, without preservatives, dyes, triclosan, microbeads, artificial sweeteners or artificial flavors. These new pastes also feature xylitol, stevia and a gentle sili- ca. "They polish those little pearlies so well, the tooth fairy's gonna need shades," said Dubitsky. Naturally friendly supermint, pink Hello (Cont'd. from p. 1) grapefruit mint and mojito mint breath sprays from Hello have all of the zing without the sting because they're free from alcohol, dyes, artificial sweeteners and propellant. Hello sprays feature glyc- erin and xylitol to keep your mouth fresh, friendly, wonderfully moisturized and ready for anything. The company's naturally friendly mouthwash also cleans, moisturizes and refreshes without the burn or sting. It fea- tures smooth, soothing glycerin and is sweetened with xylitol. According to Dubitsky, it tastes so delicious users won't want to spit it out. "Without alco- hol, dyes and artificial sweeteners, you don't have to," Dubitsky said. "Sweet." Hello also offers a line of tooth- brushes with handles made with 50 per- cent recycled materials. "They don't spin, whir or pulsate, but if you pair them with our toothpaste, your tastebuds very well may," Dubitsky said. In keeping with the friendly nature of the brand, Dubitsky also offers up this friendly reminder: "Please brush after every meal, and please replace your toothbrush, even if it's not one of ours, every 90 days or so." For more information, visit www.hello -products.com, call 855.hi.hello or email hi@hello-products.com.